
Dolutegravir (sodium)/lamivudine/tenofovi disoproxil fumarate 50 mg/300 mg/300 mg tablets (Cipla Ltd.), HA702

All accepted presentations of [HA702 trade name]*

See:

<u>https://extranet.who.int/prequal/medicines/prequalified/finished-pharmaceutical-products</u> Search for WHO reference number (as provided in the header).

Appearance



^{*} Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.